Welcome to our dedicated page for Immunic news (Ticker: IMUX), a resource for investors and traders seeking the latest updates and insights on Immunic stock.
Immunic Inc (IMUX) is a clinical-stage biopharmaceutical company pioneering oral therapies for chronic inflammatory and autoimmune diseases. This page serves as the definitive source for Immunic's latest developments, including clinical trial progress, regulatory milestones, and strategic partnerships.
Investors and researchers will find timely updates on key programs like IMU-838 for multiple sclerosis, IMU-935 for psoriasis, and IMU-856 targeting gastrointestinal disorders. Our news collection covers essential updates including FDA communications, trial result publications, and scientific conference presentations.
Bookmark this page to efficiently track Immunic's progress in advancing selective immunomodulation therapies while maintaining accessibility for both professional investors and those new to understand the company's pipeline.
Immunic, Inc. (Nasdaq: IMUX) released its fourth quarter and full year 2021 financial results, reporting a net loss of $92.9 million, or $3.93 per share, up from a loss of $44.0 million, or $2.81 per share in 2020. Cash and cash equivalents stood at $86.9 million as of December 31, 2021. The company highlighted significant clinical progress, including enrollment completion in a Phase 2 trial for vidofludimus calcium in ulcerative colitis and initiation of a Phase 1 trial for IMU-935 in metastatic prostate cancer. Upcoming data readouts and patent allowances for IMU-935 through 2038 are also noted.
Immunic, Inc. (Nasdaq: IMUX) has announced the presentation of preclinical data on vidofludimus calcium (IMU-838), a selective oral DHODH inhibitor, at the 17th Congress of European Crohn's and Colitis Organization (ECCO). The data showcases its potent anti-inflammatory activity. Key insights reveal the drug's effectiveness in managing immune responses and its potential as a combination treatment for ulcerative colitis. The company also disclosed blinded baseline characteristics of its phase 2 CALDOSE-1 trial, which enrolled 263 patients, with initial data expected in June 2022.
Immunic (Nasdaq: IMUX) will announce its financial results for Q4 and the year ended December 31, 2021, on February 24, 2022, before U.S. market opens. Following this, a webcast will be held at 8:00 am ET. The company focuses on developing selective oral immunology therapies targeting chronic inflammatory and autoimmune diseases, including multiple sclerosis and ulcerative colitis. This upcoming report may provide insights into the company's financial position and future strategy.
Immunic, Inc. (Nasdaq: IMUX) announced its participation in key investor and scientific conferences in February 2022. Notably, CEO Daniel Vitt will engage in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on February 17 at 12:00 pm ET. Additionally, Dr. Evelyn Peelen will present preclinical data on IMU-838 at the 17th Congress of ECCO from February 16-19. A company overview will also be presented at the Aegis Capital Corp. Virtual Conference on February 23 at 11:30 am ET. Webcasts and presentations will be available on Immunic's website.
Immunic, Inc. (Nasdaq: IMUX) announced a Notice of Allowance from the USPTO for patent application 16/644581 covering its oral IL-17 inhibitor, IMU-935, which has shown positive Phase 1 trial results. Additional patent allowances were received in Europe and Australia, providing market protection until at least 2038. IMU-935 aims to treat autoimmune diseases and has shown a differentiated safety profile. Ongoing trials also target moderate-to-severe psoriasis and metastatic castration-resistant prostate cancer, with expectations for initial data release soon.
On December 14, 2021, Immunic announced positive results from its Phase 1 clinical trial of IMU-935, a selective oral IL-17 inhibitor. The trial demonstrated favorable safety, tolerability, and pharmacokinetic (PK) profiles in healthy subjects during both single and multiple ascending dose phases. Key findings included a stable plasma concentration, no serious adverse events, and well-tolerated doses. The company plans to initiate Part C of the trial with moderate-to-severe psoriasis patients. These results support IMU-935's potential as a best-in-class treatment for autoimmune diseases.
Immunic, Inc. (Nasdaq: IMUX) announced the enrollment of the first patient in an open-label phase 1 trial for IMU-935, a selective inverse agonist targeting metastatic castration-resistant prostate cancer (mCRPC). Approved by UK regulatory bodies, the trial aims to evaluate safety, tolerability, and anti-tumor activity in 18-24 patients over three cycles. Initial clinical data is anticipated in Q3 2022. Preclinical data suggests IMU-935 could suppress drivers of CRPC, highlighting its potential as a treatment option for this challenging cancer.
Immunic, Inc. (Nasdaq: IMUX) announced participation in the Piper Sandler & Co. 33rd Annual Virtual Healthcare Conference from November 29 to December 2, 2021. CEO Daniel Vitt, Ph.D., will present a fireside chat available to registered attendees from November 22 to December 2. The presentation will also be accessible on Immunic's website under the 'Events and Presentations' section. Immunic focuses on developing selective oral immunology therapies for chronic inflammatory and autoimmune diseases, including lead product, vidofludimus calcium (IMU-838).
Immunic, Inc. (Nasdaq: IMUX) announced the enrollment of the first patient in its phase 3 ENSURE program for vidofludimus calcium (IMU-838) aimed at treating relapsing multiple sclerosis (RMS). This pivotal trial follows a supportive phase 2 trial and involves approximately 1,050 patients across more than 100 sites worldwide. The primary endpoint is the time to first relapse within 72 weeks. The company believes that the positive outcomes from earlier studies, including the phase 2 EMPhASIS trial, support its path toward regulatory approval.
Immunic, Inc. (Nasdaq: IMUX) reported its third-quarter financial results for 2021, revealing a net loss of $19.3 million, or $0.76 per share. The company highlighted major developments in its clinical pipeline, including the completion of patient enrollment in the CALDOSE-1 trial for IMU-838 in ulcerative colitis and the initiation of the CALLIPER trial in progressive multiple sclerosis. Financially, R&D expenses rose to $15.5 million, driven by increased clinical trial costs. The company ended the quarter with $110.4 million in cash, projected to cover operations into 2023.
